<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260805</url>
  </required_header>
  <id_info>
    <org_study_id>B3341001</org_study_id>
    <secondary_id>ICF PBIO 071/10 APH 100214</secondary_id>
    <nct_id>NCT01260805</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.</brief_title>
  <official_title>A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratórios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane® 0,02mg + 0,075mg (Schering Do Brasil Química E Farmacêutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine the&#xD;
      Bioequivalence of Ethinylestradiol + Gestodene - The objective of the study is to verify&#xD;
      through a single dose study, if the two formulations of Ethinylestradiol 0,02mg + Gestodene&#xD;
      0,075mg sugar coated tablets are bioequivalent when administered at the same dose and under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioequivalence Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maxium concentration (Cmax) for ethinylestradiol/gestodene in plasma</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma/serum/blood concentration(AUC0-t) time curve from time zero to time t for ethinylestradiol/gestodene</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC0-inf) for ethinylestradiol/gestodene</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax) for ethinylestradiol/gestodene in plasma</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination of half-life(T1/2) for ethinylestradiol/gestodene</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K el for ethinylestradiol/gestodene</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from the time of dosing (AUC t/inf) extrapolated to infinity for ethinylestradiol/gestodene</measure>
    <time_frame>Up to 96h / Up to 144h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Bioequivalence</condition>
  <condition>Ethinylestradiol</condition>
  <condition>Gestodene</condition>
  <condition>Harmonet</condition>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Drug</intervention_name>
    <description>Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose</description>
    <arm_group_label>Reference Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Drug</intervention_name>
    <description>Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose</description>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female subjects in childbearing age, between the ages of 18 and 45 years,&#xD;
             inclusive (Healthy is defined as no clinically relevant abnormalities identified by a&#xD;
             detailed medical history, full physical examination, including blood pressure and&#xD;
             pulse rate measurement, 12-lead ECG and clinical laboratory tests).&#xD;
&#xD;
          -  The BMI - Body Mass Index of the volunteers should be within the range of 18,5 to 24,9&#xD;
             (Dietary Guidelines for Americans) and it may vary up to 10% due to the upper limit&#xD;
             (18,5 to 27,39) and total body weight &gt;50kg&#xD;
&#xD;
          -  Do not be a smoker (at least 3 months);&#xD;
&#xD;
          -  Not be using hormone contraceptives for at least 28 days before the medication dosing;&#xD;
&#xD;
          -  Women with a regular menstrual cycle (menstrual cycle that occurs, in average, in each&#xD;
             28 days, varying from 25 to 35 days);&#xD;
&#xD;
          -  Use lubricated condoms with spermicidal or diaphragm with spermicidal (in accordance&#xD;
             with the volunteer's preference)&#xD;
&#xD;
          -  Systolic Pressure up to 130mmHg;&#xD;
&#xD;
          -  Diastolic Pressure up to 85mmHg;&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject or a legally acceptable&#xD;
             representative. If the subject and/or legally acceptable representative cannot read,&#xD;
             then the informed consent document may be signed by an impartial witness.&#xD;
&#xD;
          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at time of dosing).&#xD;
&#xD;
          -  The volunteer has a drug abuse history [subjects using marijuana and hashish will be&#xD;
             excluded if they have used these drugs less than three months prior to the medical&#xD;
             consult and for drugs such as cocaine, phencyclidine (PCP), crack and heroin,&#xD;
             volunteers will be excluded that have used these drugs less than 1 year prior to the&#xD;
             medical consult.&#xD;
&#xD;
          -  A positive exam for drugs in urine (Methamphetamine, Opiate, Morphine, Marijuana,&#xD;
             Cannabis, Amphetamine, Coccaine, Benzoylecgogine, Benzodiazepine) or a positive test&#xD;
             for alcohol before the internment in periods 1 and 2.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 150 mL of&#xD;
             wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening.&#xD;
&#xD;
          -  The volunteer is a smoker or having stopped smoking less than 3 months&#xD;
&#xD;
          -  The volunteer has participated of any experimental trial or has ingested any&#xD;
             experimental drug within the 6 months that precede the beginning of the study (ANVISA:&#xD;
             Resolution RDC nº34, from June 3rd 2008).&#xD;
&#xD;
          -  12-lead ECG demonstrating QTc &gt;450 msec at screening. If QTc exceeds 450 msec, the ECG&#xD;
             should be repeated two more times and the average of the three QTc values should be&#xD;
             used to determine the subject's eligibility.&#xD;
&#xD;
          -  Pregnant or nursing females; females of childbearing potential who are unwilling or&#xD;
             unable to use an acceptable method of non-hormonal contraception as outlined in this&#xD;
             protocol from at least 14 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or&#xD;
             5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal&#xD;
             medicine, herbal supplements must be discontinued 28 days prior to the first dose of&#xD;
             study medication. Limited use of non-prescription medications that are not believed to&#xD;
             affect subject safety or the overall results of the study may be permitted on a&#xD;
             case-by-case basis following approval by the sponsor.&#xD;
&#xD;
          -  Hormonal methods of contraception (including oral and transdermal contraceptives,&#xD;
             injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs,&#xD;
             postcoital contraceptive methods) and hormone replacement therapy must be discontinued&#xD;
             28 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Implant (ex. Norplant®) or a progesterone depot injection (ex. Depo-Provera®) or the&#xD;
             use of any dispositive for the long term treatment with progesterone or estrogens (ex.&#xD;
             Estring®) up to 6 months before the administration of the medication in study;&#xD;
&#xD;
          -  A depot injection or an implant of any active ingredient up to 3 months before the&#xD;
             administration of the medication in study;&#xD;
&#xD;
          -  Have used an injection contraceptive of Medroxyprogesterone Acetate one year before&#xD;
             the beginning of the study;&#xD;
&#xD;
          -  Have had sexual intercourse without a contraceptive method (preservative, IUD,&#xD;
             diaphragm with spermicidal) within the last 14 days.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aparecida de Goiania</city>
        <state>GO</state>
        <zip>74935-530</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3341001&amp;StudyName=A%20Bioequivalence%20Study%20Of%20Ethinylestradiol%20+%20Gestodene%20In%20Female%20And%20Healthy%20Volunteers.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>study</keyword>
  <keyword>ethinylestradiol</keyword>
  <keyword>gestodene</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

